Thursday, 30 July 2009
AstraZeneca’s business performance, in the context of tough global economic conditions, has been better than anticipated. The strong first half performance is reflected in the increased Core EPS target for the full year and continued progress has been made on the pipeline.
Download the Narrative (PDF 86kb) and the Figures (PDF 117kb)
CONTACTS:
Media Enquiries:
Neil McCrae +44 207 304 5045 (24 hours)
Chris Sampson +44 20 7304 5130 (24 hours)
Sarah Lindgreen +44 20 7304 5033 (24 hours)
Investor Enquiries UK:
Jonathan Hunt +44 207 304 5087 mob: +44 7775 704032
Karl Hard +44 207 304 5322 mob: +44 7789 654364
Investor Enquiries US:
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043